土耳其制药行业市场前景及投资研究报告-外文版培训课件2024.7

INDUSTRIES

&

MARKETSPharmaceuticalindustryinTurkeyCHAPTER

01EuropeanmarketoverviewPharmaceuticalmarketvalueinselectedEuropeancountriesin2022(inmillioneuros)MarketvalueofpharmaceuticalindustrybyEuropeancountry2022Marketvalueinmillioneuros010,00020,00030,00040,00050,00060,000GermanyFrance50,60935,328UnitedKingdomItaly28,85325,808SpainRussia19,57218,398Poland8,911NetherlandsBelgium7,6757,064SwitzerlandTurkey7,0276,985RomaniaAustria5,7495,7194Description:Thisstatisticdisplaysthepharmaceuticalindustry'smarketvalueinEuropebyselectedcountriesin2022.ThepharmaceuticalmarketinDenmarkwasvaluedataround3.6billioneurosinthatyear.Germanywasthetop-rankedpharmaceuticalmarketinEuropeduringthatyear,withavalueofover50billioneuros.ReadmoreNote(s):Europe;2022Source(s):EFPIA;IQVIAPharmaceuticalproductioninselectedEuropeancountriesin2022(inmillioneuros)ProductioninEuropeanpharmaceuticalindustrybycountry2022Productioninmillioneuros30,000010,00020,00040,00050,00060,000SwitzerlandItaly56,64149,000Belgium40,959GermanyFrance37,40532,773UnitedKingdomSpain29,04422,95721,501DenmarkIreland19,305Sweden11,910SloveniaRussiaNetherlands6,9556,4596,1805/statistics/315964/european-pharmaceutical-industry-production-by-select-countriesThisstatisticdisplaystheEuropeanpharmaceuticalindustry'sproductionbyselectedcountriesin2022(orlatestyearavailable).ThepharmaceuticalindustryinSwitzerlandproducedpharmaceuticalproductsworthanestimated56.6billioneurosin2022.ReadmoreNote(s):Europe;2022Source(s):EFPIAPharmaceuticalemploymentinselectedEuropeancountriesin2022EmploymentinEuropeanpharmaceuticalindustrybycountry2022Numberofemployees020,00040,00060,00080,000100,000120,000140,000GermanyFrance123,47595,867UnitedKingdomItaly70,00068,600SpainSwitzerlandIreland50,60047,60045,00043,50142,29139,81534,800BelgiumTurkeyDenmarkHungaryRomaniaGreece33,55032,6376Description:ThisstatisticdepictstheEuropeanpharmaceuticalindustry'semploymentbyselectedcountriesin2022(orlatestyearavailable).ThepharmaceuticalindustryinDenmarkemployednearly40thousandpersonsinthatyear.Thus,Denmarkwasrankedinthemiddlebasedonpharmaceuticalemployees.ReadmoreNote(s):Europe;2022Source(s):EFPIAMarketshareofgenericsandbiosimilarsinselectedEuropeancountriesin2022MarketshareofgenericsinEuropeancountries2022Shareofpharmaceuticalmarketsalesvalue20%

30%

40%0%10%50%60%70%AustriaPoland58%54%Latvia47%Croatia40%HungaryDenmarkRussia36.8%33%31.6%31.6%30.2%29.6%TurkeyNorwayBulgariaNetherlandsGreece29%28.7%Serbia27.8%7Description:ThisstatisticdisplaystheshareofgenericsinthepharmaceuticalmarketsalesvalueinEuropebyselectedcountriesin2022,includingalsobiosimilars.Thegenericshareinthepharmaceuticalindustry'smarketsalesinDenmarkstoodat33percent.ThemarketshareofgenericsishigherinnewerEUmemberstatesduetolowerlevelsofintellectualpropertyprotection.ReadmoreNote(s):Europe;2022Source(s):EFPIACHAPTER

02TurkishmarketoverviewRevenueofthepharmaceuticalsmarketinTurkeyfrom2016to2027(inmillionU.S.dollars)RevenueofthepharmaceuticalsmarketinTurkey2016-20274,5004,0654,0003,5003,0002,5002,0001,5001,0005003,8073,6033,4083,3723,1982,1772,0702,0291,9591,9011,89002016201720182019202020212022202320242025202620279Description:Afterpeakingin2016atoverfourbillionU.S.dollars,therevenueoftheTurkishpharmaceuticalsmarketgenerallydecreasedwithsomeoscillationovertheobservedperiod.In2022,theestimatedrevenueofthemarketamountedtoabouttwobillionU.S.dollars.TherevenueofthepharmaceuticalsmarketinTurkeywasforecasttoincreasebetween2023and2027by276millionU.S.dollars(+14.52percent).Thisoverallincreasedoesnothappencontinuously,notablynotin2024.The[...]

ReadmoreNote(s):Turkey;2016to2027Source(s):HealthMarketInsightsSalesvalueofthepharmaceuticalmarketinTurkeyfrom2010to2023(inbillionTurkishlira)PharmaceuticalmarketsalesvalueinTurkey2010-202325020015010050211109.861.847.940.730.924.520.417.613.413.612.913.71502010201120122013201420152016201720182019202020212022202310Description:ThetotalsalesvalueoftheTurkishpharmaceuticalmarketincreasedconstantlybetween2010and2023.In2023,thepharmaceuticalmarketinTurkeyhadatotalsalesvalueof211billionTurkishlira,whichindicatedarecordsalesvalueintheobservedperiod.ReadmoreNote(s):Turkey;2010to2023Source(s):IQVIA;PharmaceuticalManufacturersAssociationofTurkeyNumberofunitssoldinthepharmaceuticalmarketinTurkeyfrom2010to2023(inbillions)NumberofpharmaceuticalunitssoldinTurkey2010-20233.02.52.672.552.372.352.32.222.22.152.061.922.01.51.00.50.01.861.831.791.622010201120122013201420152016201720182019202020212022202311Description:ThenumberofunitssoldannuallyinthepharmaceuticalmarketinTurkeymostlyincreasedfrom2010to2023.In2023,therewereapproximately2.67billionunitsalesintheTurkishpharmaceuticalmarket,whichindicatedarecordnumberofunitssoldintheobservedperiod.ReadmoreNote(s):Turkey;2010to2023Source(s):IQVIA;PharmaceuticalManufacturersAssociationofTurkeyRevenueoftheOTCpharmaceuticalsmarketinTurkeyfrom2018to2027(inmillionU.S.dollars)OTCpharmaceuticalsrevenueinTurkey2018-2027300266.9263.5259257.526024425020015010050224.4209.2207194.80201820192020202120222023202420252026202712Description:In2022,over-the-counterpharmaceuticalsmarketgeneratedarevenueof209.2millionU.S.dollarsinTurkey.Accordingtotheestimationofincreasebetween2023and2027,namelyby68.7millionU.S.dollars.ReadmoreNote(s):Turkey;2018to2027HealthMarketOutlook,therevenueoftheOTCpharmaceuticalsmarketisforecasttosignificantlySource(s):HealthMarketInsightsSalesvalueofmedicinalproductsinTurkeyfrom2015to2023(inbillionTurkishlira)SalesvalueofmedicinalproductsinTurkey2015-20231412108137.4563.8242.941.8321.51.111.110.93020152016201720182019202020212022202313/statistics/984735/medicinal-products-market-in-turkeyThefiguresforthetotalsalesvalueofmedicinalproductsinTurkeyshowedaconsistentincreasefrom2015to2023.In2023,thesalesvalueofmedicinalproductsreached13billionTurkishlira,byfarthehighestfigureintheprovidedtimeinterval.

ReadmoreNote(s):Turkey;2015to2023Source(s):IQVIA;PharmaceuticalManufacturersAssociationofTurkeySalesvolumeofmedicinalproductsinTurkeyfrom2015to2023(inmillionunits)SalesvolumeofmedicinalproductsinTurkey2015-202312010098978077806865615958604020020152016201720182019202020212022202314Description:ThesalesvolumeofmedicinalproductsinTurkeyfluctuatedfrom2015to2023.In2022,thesalesvolumeofmedicinalproductsamountedto97millionunits.ReadmoreNote(s):Turkey;2015to2023Source(s):IQVIA;PharmaceuticalManufacturersAssociationofTurkeyNumberofpeopleemployedinpharmaceuticalindustryinTurkeyfrom2010to2022(in1,000s)EmploymentlevelinthepharmaceuticalindustryinTurkey2010-20225045403547.5144.0742.2939.0737.7935.553331.5631.3731.4630.929.6229.29302520151050201020112012201320142015201620172018201920202021202215Description:ThetotalnumberofpeopleemployedinthepharmaceuticalindustryinTurkeyconsistentlyincreasedfrom2014to2022.Asof2022,therewereover47,500employeesinthepharmaceuticalindustry.

ReadmoreNote(s):Turkey;2010to2022Source(s):PharmaceuticalManufacturersAssociationofTurkey;TurkStatPharmaceuticalsectorspendingonresearchanddevelopment(R&D)inTurkeyfrom2010to2022(inmillionTurkishlira)PharmaceuticalR&DspendinginTurkey2010-20222,5002,0001,5001,0005002,081.91,104.2676.22020644.32018499.72019369.82016357.52017250.62015210.32013219.22014194.22011191.5201292.1020102021202216Description:TheamountspentonresearchanddevelopmentbythepharmaceuticalsectorinTurkeygenerallywentupbetween2010and2022.In2022,pharmaceuticalsectorspendingonR&DnotablyincreasedfromthepreviousyearandpeakedatoverthreebillionTurkishlira.ReadmoreNote(s):Turkey;2010to2022Source(s):PharmaceuticalManufacturersAssociationofTurkey;TurkStatNumberofaccreditedresearchanddevelopmentcentersinpharmaceuticalindustryinTurkeyfrom2010to2023NumberofaccreditedR&DcentersinpharmaceuticalindustryinTurkey2010-2023504540434239353025201510533333024171210754402010201120122013201420152016201720182019202020212022202317Description:Thetotalnumberofaccreditedresearchanddevelopment(R&D)centersinthepharmaceuticalsectorinTurkeyconsistentlywentupfrom2010to2023.In2010,therewereonlyfouraccreditedR&DcentersinTurkey,by2023thisfigurehadincreasedto43.ReadmoreNote(s):Turkey;2010to2023Source(s):IQVIA;PharmaceuticalManufacturersAssociationofTurkeyCHAPTER

03SegmentsRevenueofthepharmaceuticalsmarketinTurkeyfrom2018to2027,bysegment(inmillionU.S.dollars)RevenueofthepharmaceuticalsmarketinTurkey2018-2027,bysegmentAnti-CoagulantsAntiviralDrugsMultipleSclerosisDrugsAnti-DiabetesDrugsBronchodilatorDrugsOncologyDrugsAnti-FibrinolyticsDrugsDermatologicalDrugsOtherPharmaceuticalsAnti-HypertensiveDrugsImmunosuppressantsSensoryOrgansDrugsAnti-RheumaticDrugsLipid-LoweringAgentsVaccines4,0003,5003,0002,5002,0001,5001,0005000201820192020202120222023202420252026202719Description:Overtheupcomingyears,therevenueoftheTurkishpharmaceuticalsmarketisforecasttoincreaseinallsegments.Concerningtheselectedsegments,vaccineshadthelargestrevenuein2022with483millionU.S.dollars.Itwasfollowedbyoncologydrugs,recording258.3millionU.S.dollarsofrevenueinthesameyear.ReadmoreNote(s):Turkey;2018to2027Source(s):HealthMarketInsightsRevenueoftheover-the-counter(OTC)pharmaceuticalsmarketinTurkeyfrom2018to2027,bysegment(inmillionU.S.dollars)RevenueoftheOTCpharmaceuticalsmarketinTurkey2018-2027,bysegmentAnalgesicsVitamins&MineralsCold&CoughRemediesDigestives&IntestinalRemediesSkinTreatmentHandSanitizer300250200150100500201820192020202120222023202420252026202720Description:In2022,analgesicsrecordedthehighestrevenuewithover101millionU.S.dollarsamongallsegmentsoftheover-the-counter(OTC)pharmaceuticalsmarketinTurkey.Rankingsecond,thevitaminsandmineralssegmentgeneratedarevenueof74.3millionU.S.dollars.Allsegmentsoftheover-the-counter(OTC)pharmaceuticalsmarketinTurkeyareforecasttoincreasetheirrevenueovertheupcomingyearsexceptforthehandsanitizersegment.

ReadmoreNote(s):Turkey;2018to2027Source(s):HealthMarketInsightsValueoflocallyproducedpharmaceuticalproductsinTurkeyfrom2010to2023(inbillionTurkishlira)ValueoflocalpharmaceuticalproductsinTurkey2010-202314012010080122.160604032.424.321.22014.911.29.17.55.865.866.502010201120122013201420152016201720182019202020212022202321Description:ThetotalvalueoflocallyproducedpharmaceuticalproductsinTurkeywentupconstantlyfrom2010to2023.In2023,thevalueofpharmaceuticalproductsmanufacturedintheTurkishmarkethasalmostdoubledcomparedtothepreviousyear,reaching122billionTurkishlira.ReadmoreNote(s):Turkey;2010to2023Source(s):IQVIA;PharmaceuticalManufacturersAssociationofTurkeyVolumeoflocallyproducedpharmaceuticalproductsinTurkeyfrom2010to2023(inbillionboxes)VolumeoflocalpharmaceuticalproductsinTurkey2010-20233.02.52.02.442.312.092.071.931.941.791.721.631.51.51.51.41.51.00.50.01.32010201120122013201420152016201720182019202020212022202322/statistics/984695/local-pharmaceutical-products-in-turkeyThetotalvolumeoflocallyproducedpharmaceuticalproductsinTurkeyfluctuatedfrom2010to2023.Thevolumeoflocalpharmaceuticalproductsreachedover2.4billionboxesin2023,whichwasthepeakamountduringtheobservedperiod.

ReadmoreNote(s):Turkey;2010to2023Source(s):IQVIA;PharmaceuticalManufacturersAssociationofTurkeyValueoforiginatormedicinemarketinTurkeyfrom2010to2023(inbillionTurkishlira)ValueoforiginatormedicinemarketinTurkey2010-20231401201008013171.46041.94032.7272116.72013.912.210.49.39.28.79.502010201120122013201420152016201720182019202020212022202323/statistics/984503/originator-medicine-market-in-turkeyThetotalvalueoftheoriginatormedicine(brandeddrugs)marketinTurkeyincreasedconstantlyfrom2012to2023.Thetotalvaluepeakedin2023andreached131billionTurkishlira.Thelowestvaluewasrecordedin2012,at8.7billionTurkishlira.

ReadmoreNote(s):Turkey;2010to2023Source(s):IQVIA;PharmaceuticalManufacturersAssociationofTurkeyVolumeoforiginatormedicinemarketinTurkeyfrom2010to2023(inbillionboxes)VolumeoforiginatormedicinemarketinTurkey2010-20231.21.00.990.970.950.930.920.920.90.90.90.890.80.80.80.80.80.60.40.20.02010201120122013201420152016201720182019202020212022202324Description:Thetotalvolumeoftheoriginatormedicine(brandeddrugs)marketgenerallyfollowedanincreasingtrendinTurkeyfrom2010to2023.In2022,thevolumeoftheoriginatormedicinemarketpeakedatalmostonebillionboxes.By2023,thevolumeslightlydecreasedto0.97billionboxes.ReadmoreNote(s):Turkey;2010to2023Source(s):IQVIA;PharmaceuticalManufacturersAssociationofTurkeyValueofgenericpharmaceuticalmarketinTurkeyfrom2010to2023(inbillionTurkishlira)ValueofgenericpharmaceuticalmarketinTurkey2010-20239080706050403020108038.419.815.213.79.97.96.55.44.24.44.14.34.602010201120122013201420152016201720182019202020212022202325Description:ThetotalvalueofthegenericpharmaceuticalmarketinTurkeycontinuallyincreasedfrom2012to2023.Thetotalvaluepeakedin2022,reaching80billionTurkishlira.In2012,thegenericmarketwasworth4.1billionTurkishlira,whichwastheyearwiththelowestgenericproductsvaluerecordedduringtheperiodinconsideration.ReadmoreNote(s):Turkey;2010to2023Source(s):IQVIA;PharmaceuticalManufacturersAssociationofTurkeyVolumeofgenericpharmaceuticalmarketinTurkeyfrom2010to2023(inbillionboxes)VolumeofgenericpharmaceuticalmarketinTurkey2010-20231.81.61.41.21.71.561.441.41.371.311.311.251.161.11111.00.80.60.40.20.00.92010201120122013201420152016201720182019202020212022202326Description:ThetotalvolumeofthegenericpharmaceuticalmarketinTurkeygenerallyincreasewithsomefluctuationsfrom2010to2023.In2023,thevolumeofthegenericsmarketreachedaround1.7billionboxes,whichwasthehighestvaluerecordedduringtheshowntimeline.ReadmoreNote(s):Turkey;2010to2023Source(s):IQVIA;PharmaceuticalManufacturersAssociationofTurkeyCHAPTER

04PricesAveragepriceofpharmaceuticalsperpackageinTurkeyfrom2015to2023(inTurkishlira)AveragepriceofpharmaceuticalsperpackageinTurkey2015-20239080706050403078.942.9926.23202122.77202017.2120192013.43201811.039.498.521002015201620172022202328Description:TheaveragepriceofpharmaceuticalsperboxontheTurkishmarkethadconsistentlyincreasedbetween2015and2023.In2023,theaveragepriceperboxwentupsignificantly,peakingatnearly79lira.

ReadmoreNote(s):Turkey;2015to2023Source(s):IQVIA;PharmaceuticalManufacturersAssociationofTurkeyAveragepriceofdomesticallyproducedmedicinesperpackageinTurkeyfrom2015to2023(inTurkishlira)AveragepriceofdomesticallyproducedmedicinesperpackageinTurkey2015-202360504030205025.9915.51202112.55202010.2220191007.756.255.284.5920152016201720182022202329Description:TheaveragepriceoflocallyproducedmedicinesperboxinTurkeyincreasedeveryyearovertheobservedperiod.In2023,theaveragepriceofdomesticallyproducedmedicinesperboxamountedto50Turkishlira,whichrepresenteda989.6percentincreasecomparedtothepricerecordedin2015.ReadmoreNote(s):Turkey;2015to2023Source(s):IQVIA;PharmaceuticalManufacturersAssociationofTurkeyAveragepriceofimportedmedicinesperpackageinTurkeyfrom2015to2023(inTurkishlira)AveragepriceofimportedmedicinesperpackageinTurkey2015-2023450400350300250200150100388.2202.81109.69202189.01202066.82201942.25201850030.94201726.123.5201520162022202330/statistics/1409845/turkey-average-price-of-imported-medicinesTheaveragepriceofimportedpharmaceuticalsperboxinTurkeyconsistentlywentupbetween2015and2023.In2023,theaveragepriceofimporteddrugsalmostdoubledcomparedtothepreviousyear,reachingabove388Turkishliraperbox.

ReadmoreNote(s):Turkey;2015to2023Source(s):IQVIA;PharmaceuticalManufacturersAssociationofTurkeyAveragepriceoforiginatorandgenericmedicinesperpackageinTurkeyfrom2015to2023(inTurkishlira)AveragepriceoforiginatorandgenericmedicinesperpackageinTurkey2015-2023OriginatorGeneric160134.41401201008071.986047.14436.814029.2324.5722.4918.1615.3613.5514.1320011.579.537.244.635.236.0220152016201720182019202020212022202331Description:Overtheobservedperiod,originatordrugscostsignificantlyhigherthangenericdrugs.In2023,theaveragepriceoforiginatormedicineamountedtoover134TurkishliraperboxinTurkey.Incomparison,theaveragepriceofgenericmedicinetotaled47Turkishliraperbox.ReadmoreNote(s):Turkey;2015to2023Source(s):IQVIA;PharmaceuticalManufacturersAssociationofTurkeyCHAPTER

05ConsumptionConsumptionofpharmaceuticalsinTurkeyin2021,bymedicinetype(inDDDper1,000inhabitantsperday)ConsumptionofpharmaceuticalsinTurkey2021,bymedicinetypeDefineddailydosageperthousandinhabitants50

100

1500200250300350400450500AlimentarytractandmetabolismCardiovascularsystem441.6221.7Bloodandbloodformingorgans188.1NervoussystemAgentsactingontheRenin-AngiotensinsystemRespiratorysystem11398.498.296.3DrugsusedindiabetesDrugsforpepticulcerandgastro-oesophagealrefluxdiseases(GORD)GenitourinarysystemandsexhormonesMusculo-skeletalsystem8380.965.153.752.544.2Antiinflammatoryandantirheumaticproductsnon-steroidsAntidepressantsDrugsforobstructiveairwaydiseases33Description:In2021,themostconsumedpharmaceuticaltypeinTurkeywasalimentarytractandmetabolismmedicineswith441.6dosagesper1,000inhabitantsperday.Cardiovascularsystemdrugsfollowedassecondmostconsumedtype,averagingabout222dailydosageper1,000inhabitants.ReadmoreNote(s):Turkey;2021Source(s):OECDConsumptionofalimentarytractandmetabolismpharmaceuticalsTurkeyfrom2010to2021(inDDDper1,000inhabitantsperday)AlimentarytractandmetabolismpharmaceuticalconsumptioninTurkey2010-2021500441.6450417.3392.4387.440035030025020015010050340.6332.7286.2224199.1185.42012170.920111470201020132014201520162017201820192020202134Description:TheconsumptionofalimentarytractandmetabolismpharmaceuticalsinTurkeyincreasedby200.4percentin2021comparedto2010.In2021,441.6dosagesper1,000inhabitantsperdaywererecordedinthecountry,theconsumptiontherebyreacheditshighestvalueintheobservedperiod.ReadmoreNote(s):Turkey;2010to2021Source(s):OECDConsumptionofcardiovascularsystempharmaceuticalsinTurkeyfrom2010to2021(inDDDper1,000inhabitantsperday)CardiovascularsystempharmaceuticalconsumptioninTurkey2010-2021250221.7218.8195.1200187.7176.4167.4165.4162.8163.3160.8158.9151.715010050020102011201220132014201520162017201820192020202135Description:TheconsumptionofcardiovascularsystempharmaceuticalscontinuouslyincreasedinTurkeyovertheobservedperiod.In2021,theconsumptionofcardiovascularsystemdrugspeakedatanaverageof221.7dosagesper1,000inhabitantsperday.Inthesameyear,medicationsforthecardiovascularsystembecamethesecondmostconsumedmedicinetypeinTurkey.ReadmoreNote(s):Turkey;2010to2022Source(s):OECDConsumptionofdrugsactingonthebloodandblood-formingorgansinTurkeyfrom2010to2021(inDDDper1,000inhabitantsperday)Consumptionofdrugsactingonthebloodandblood-formingorgansinTurkey2010-2021200188.118016014012010080169.3170.2152.8144.4134.6124.4118111.3107.296.587.2604020020102011201220132014201520162017201820192020202136Description:In2021,theconsumptionofdrugsactingonthebloodandblood-formingorgansinTurkeyincreasedbyabout35dosagesper1,000inhabitantsperday(+23percent)comparedto2020.Overall,theconsumptionamountedto188dosagesper1,000inhabitantsperdayin2021.ReadmoreNote(s):Turkey;2010to2021;defineddailydosageper1,000inhabitantsperdaySource(s):OECDConsumptionofantidepressantsinTurkeyfrom2010to2021(inDDDper1,000inhabitantsperday)AntidepressantspharmaceuticalconsumptioninTurkey2010-2021605052.548.944.144.243.540.74138.140302010037.33736.332.720102011201220132014201520162017201820192020202137Description:TheconsumptionofantidepressantsinTurkeyincreasedby3.6dosagesper1,000inhabitantsperday(+7.36percent)in2021comparedtothepreviousyear.Intotal,theconsumptionamountedto52.5dosagesper1,000inhabitantsperdayin2021,whichwasthehighestfigurerecordedovertheobservedperiod.ReadmoreNote(s):Turkey;2010to2021Source(s):OECDCHAPTER

06TradeImportvalueofTurkey'spharmaceuticalindustryfrom2015to2023(inbillionU.S.dollars)ImportvaluepharmaceuticalindustryTurkey2015-20238767.525.745.645.565.325.135.054.944.7654321020152016201720182019202020212022202339Description:ThetotalvalueofimportsoftheTurkishpharmaceuticalindustrygenerallyincreasedovertheobservedtimeframe,withsomefluctuations.Afterpeakingin2021at7.5billionU.S.dollars,thevalueofimportsshowedadecreasein2023andtotaled5.74billionU.S.dollars.ReadmoreNote(s):Turkey;2015to2023Source(s):PharmaceuticalManufacturersAssociationofTurkey;TurkStatValueofpharmaceuticalproductsimportedtoTurkeyfrom2011to2023(inmillionU.S.dollars)ImportvalueofpharmaceuticalproductsinTurkey2011-20238,0007,0006,0005,0004,0003,0002,0001,0000201120122013201420152016201720182019202020212022202340Description:Overtheperiodobserved,thetotalvalueofpharmaceuticalproductsimportedtoTurkeyfluctuated,peakingin2021atnearly6.9billionU.S.dollars.In2023,theimportvalueofpharmaceuticalproductsreachedapproximatelyfivebillionU.S.dollars,markinganincreasecomparedtothepreviousyear.ReadmoreNote(s):Turkey;2011to2023Source(s):UNComtradeVolumeofimportedpharmaceuticalproductsinTurkeyfrom2010to2023(inbillionboxes)VolumeofpharmaceuticalproductsimportedintoTurkey2010-20230.50.50.430.430.430.40.40.40.40.40.40.30.30.20.20.10.10.00.380.30.290.270.270.250.232010201120122013201420152016201720182019202020212022202341Description:ThetotalvolumeofimportedpharmaceuticalproductsinTurkeymostlydecreasedfrom2010to2023.Theimportvolumeamountedtoaround230millionboxesin2023,whichindicatedthelowestamountintheobservedperiod.

ReadmoreNote(s):Turkey;2010to2023Source(s):IQVIA;PharmaceuticalManufacturersAssociationofTurkeyValueofpharmaceuticalproductsimportedintoTurkeyfromin2023,bycountry(inmillionU.S.dollars)ImportvalueofpharmaceuticalproductsinTurkey2023,bycountry1,2009691,00080060040020007785264413773533483272722071601231201129542Description:In2023,Germanywastheleadingcountry,havingthehighestvalueofpharmaceuticalproductsimportedintoTurkey,reaching969millionU.S.dollarsinimportvalue.TheUnitedStatesandChinafollowedintheranking,with778and526millionU.S.dollarsworthofpharmaceuticalproductsimportedintoTurkey,respectively.ReadmoreNote(s):Turkey;2023Source(s):PharmaceuticalManufacturersAssociationofTurkey;TurkStatExportvalueofTurkey'spharmaceuticalindustryfrom2015to2023(inbillionU.S.dollars)ExportvaluepharmaceuticalindustryTurkey2015-20232.52.02.231.911.921.841.441.51.311.11.020.971.00.50.020152016201720182019202020212022202343Description:ThetotalvalueofexportsoftheTurkishpharmaceuticalindustrygenerallyincreasedfrom2015to2023.In2023,theexportvaluepeakedat2.23billionU.S.dollars.ReadmoreNote(s):Turkey;2015to2023Source(s):PharmaceuticalManufacturersAssociationofTurkey;TurkStatValueofpharmaceuticalproductsexportedfromTurkeyfrom2011to2023(inmillionU.S.dollars)ExportvalueofpharmaceuticalproductsinTurkey2011-20232,5002,0002,199.371,905.031,899.021,826.051,430.671,5001,310.091,051.91,038.52995.17981.59933.351,0005000661.782012566.820112013201420152016201720182019202020212022202344Description:ThevalueofpharmaceuticalproductsexportedfromTurkeygenerallyincreasedwithsomeoscillationfrom2011to2023.In2023,theexportvalueofpharmaceuticalproductsreachednearly2.2billionU.S.dollars,indicatingthepeakfigurethroughouttheobservedperiod.ReadmoreNote(s):Turkey;2011to2023Source(s):UNComtradeVolumeofexportsinpharmaceuticalind